PGNY Progyny (PGNY) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-misc health & allied services, nec · CIK 0001551306
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
155
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $746.6K priced
What the filings say about PGNY
Insiders, 180 days
-$1.5M net sold
6 sellers · 13% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2024-12-06
Planned sales (Form 144), 90 days
$466.3K
3 notices
Progyny insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Progyny, Inc. insiders sold a net $1.5M of stock across 728 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jul 14, 2026.
- The trade is 2.8% of the 66,496 shares held after it.
- 1 other insider sold within 30 days.
- 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Cummings Melissa B sold about $52.6K of PGNY under a 10b5-1 plan on Oct 14, 2026; 1 other insider sold within 30 days and 155 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jun 4, 2026.
- The trade is 5.1% of the 75,816 shares held after it.
- 2 other insiders sold within 30 days.
- 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GC Swartz Allison sold about $101.9K of PGNY under a 10b5-1 plan on Sep 23, 2026; 2 other insiders sold within 30 days and 155 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on May 27, 2026.
- The trade is 169.3% of the 6,792 shares held after it.
- 1 other insider sold within 30 days.
- 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GORDON KEVIN K sold about $311.9K of PGNY on Sep 10, 2026; 1 other insider sold within 30 days and 155 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 19, 2026.
- The trade is 3.2% of the 69,934 shares held after it.
- No other insider sold within 30 days.
- 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Cummings Melissa B sold about $70.9K of PGNY on Jul 14, 2026; 155 funds added in the latest 13F quarter.Context
- 19 earlier Form 4 trades (code P or S) here by this insider (19 sales), the last on Jun 2, 2026.
- The trade is 0.8% of the 74,688 shares held after it.
- 5 other insiders sold within 30 days.
- 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Livingston Mark S. sold about $15.3K of PGNY on Jun 4, 2026; 5 other insiders sold within 30 days and 155 funds added in the latest 13F quarter.728 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.5M over 180 days
-$466.3K over 90 days
below 51% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
155 funds bought in last quarter
more than 63% of Healthcare Services
Revenue
+10.4% year over year
below 53% of Healthcare Services
Margin
4.5% net margin
more than 68% of Healthcare Services
Buybacks
$148.6M repurchased, FY to 2026-06-30
more than 74% of Healthcare Services
Short interest
7.2% of the float short (float per yahoo 2026-10-26) · 4.1 days to cover · settled 2026-09-30
more than 74% of Healthcare Services
What changed in the last 30 days
Oct 16Chief Operating Officer Cummings Melissa B sold $52.6K under a 10b5-1 plan (Oct 14)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 14Officer Cummings Melissa B filed to sell $52.6K by Oct 14 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Sep 28EVP, GC Swartz Allison sold $101.9K under a 10b5-1 plan (Sep 23)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Watch PGNY
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+51.1%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PGNY: institutional holders (13F)
13F holdings, latest reported quarter
11,599,921 sh
$334.4M
7,004,280 sh
$201.9M
5,019,465 sh
$144.7M
3,210,723 sh
$92.6M
3,022,859 sh
$87.1M
Congress trades in PGNY
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2024-12-06 · disclosed 39 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PGNY planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Cummings Melissa B
Filed 2026-10-14
$52.6K
Swartz Allison
Filed 2026-09-23
$101.9K
GORDON KEVIN K
Filed 2026-09-10
$311.9K
Cummings Melissa B
Filed 2026-07-14
$70.9K
PGNY mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Easterly Snow Small Cap Value Fund
$2.1M position · as of 2026-05-31
4.6%
Touchstone Variable Series Trust-Touchstone Small Company Fund
$2.2M position · as of 2026-06-30
3.3%
Touchstone Strategic Trust-Touchstone Small Company Fund
$55.9M position · as of 2026-06-30
3.3%
Towle Value ETF
$5.4M position · as of 2026-05-29
2.7%
State Street(R) SPDR(R) S&P(R) Health Care Services ETF
$2.5M position · as of 2026-06-30
1.8%
Easterly Snow Long/Short Opportunity Fund
$1.9M position · as of 2026-05-31
1.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Schlanger
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.2M
$10.3M
$2.1M
-39%
+36%
2024
$1.4M
-$16.0M
$6.5M
-37%
+35%
2023
$1.1M
$7.3M
$986.1K
+35%
+34%
2022
$68.6M
$31.3M
$9.3M
+13%
+33%
2021
$862.5K
$12.7M
$5.4M
+83%
+38%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.5M sold by insiders over 180 days, 155 funds added last quarter, $466.3K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
PGNY financials
Revenue growth
+10.4%
XBRL, annual
Net margin
4.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.3B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PGNY
| FY Dec 2025 | $1.3B |
| FY Dec 2024 | $1.2B |
| FY Dec 2023 | $1.1B |
| FY Dec 2022 | $786.9M |
| FY Dec 2021 | $500.6M |
| Jun 2026 | $350.5M |
| Mar 2026 | $328.5M |
| Dec 2025 | $318.4M |
| Sep 2025 | $313.3M |
| Jun 2025 | $332.9M |
| Mar 2025 | $324.0M |
| Dec 2024 | $298.4M |
| Sep 2024 | $286.6M |
At each fiscal year end
Single quarter
Net margin, TTM
+6.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PGNY
| FY Dec 2025 | +4.5% |
| FY Dec 2024 | +4.7% |
| FY Dec 2023 | +5.7% |
| FY Dec 2022 | +3.9% |
| FY Dec 2021 | +13.1% |
| Jun 2026 | +8.0% |
| Mar 2026 | +7.4% |
| Dec 2025 | +3.9% |
| Sep 2025 | +4.4% |
| Jun 2025 | +5.1% |
| Mar 2025 | +4.6% |
| Dec 2024 | +3.5% |
| Sep 2024 | +3.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$178.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PGNY
| FY Dec 2025 | $191.8M |
| FY Dec 2024 | $173.7M |
| FY Dec 2023 | $185.2M |
| FY Dec 2022 | $77.2M |
| FY Dec 2021 | $23.9M |
| Jun 2026 | $44.2M |
| Mar 2026 | $39.6M |
| Dec 2025 | $48.6M |
| Sep 2025 | $46.0M |
| Jun 2025 | $50.2M |
| Mar 2025 | $47.0M |
| Dec 2024 | $50.3M |
| Sep 2024 | $42.7M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
current debt only, 2018-12-31 (91 months older than the period end); equity 2026-06-30
Debt to equity PGNY
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
795.45x
TTM operating cash flow over current debt only, 2018-12-31 (91 months older than the period end)
Cash flow to debt PGNY
| FY Dec 2025 | 830.80x |
| FY Dec 2024 | 707.92x |
| FY Dec 2023 | 746.30x |
| FY Dec 2022 | 317.77x |
| FY Dec 2021 | 102.91x |
| Jun 2026 | 795.45x |
| Mar 2026 | 815.55x |
| Dec 2025 | 830.80x |
| Sep 2025 | 822.74x |
| Jun 2025 | 798.41x |
| Mar 2025 | 803.09x |
| Dec 2024 | 707.92x |
| Sep 2024 | 650.59x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+16.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PGNY
| FY Dec 2025 | +12.5% |
| FY Dec 2024 | +11.1% |
| FY Dec 2023 | +13.3% |
| FY Dec 2022 | +9.7% |
| FY Dec 2021 | +31.4% |
| Jun 2026 | +16.2% |
| Mar 2026 | +14.9% |
| Dec 2025 | +12.5% |
| Sep 2025 | +11.4% |
| Jun 2025 | +10.9% |
| Mar 2025 | +10.1% |
| Dec 2024 | +11.1% |
| Sep 2024 | +12.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+10.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PGNY
| FY Dec 2025 | +8.7% |
| FY Dec 2024 | +8.0% |
| FY Dec 2023 | +9.5% |
| FY Dec 2022 | +6.7% |
| FY Dec 2021 | +21.5% |
| Jun 2026 | +10.6% |
| Mar 2026 | +9.5% |
| Dec 2025 | +8.7% |
| Sep 2025 | +7.8% |
| Jun 2025 | +7.3% |
| Mar 2025 | +6.9% |
| Dec 2024 | +8.0% |
| Sep 2024 | +8.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+21.5%
operating income after a 34.4% effective tax rate, over current debt only, 2018-12-31 (91 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital PGNY
| FY Dec 2025 | +15.7% |
| FY Dec 2024 | +12.3% |
| FY Dec 2023 | +15.3% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +21.5% |
| Mar 2026 | +18.5% |
| Dec 2025 | +15.7% |
| Sep 2025 | +13.2% |
| Jun 2025 | +12.3% |
| Mar 2025 | +10.8% |
| Dec 2024 | +12.3% |
| Sep 2024 | +13.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+22.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PGNY
| FY Dec 2025 | +17.4% |
| FY Dec 2024 | +13.4% |
| FY Dec 2023 | +13.0% |
| FY Dec 2022 | +7.3% |
| FY Dec 2021 | +14.9% |
| Jun 2026 | +22.1% |
| Mar 2026 | +20.2% |
| Dec 2025 | +17.4% |
| Sep 2025 | +16.6% |
| Jun 2025 | +15.1% |
| Mar 2025 | +13.5% |
| Dec 2024 | +13.4% |
| Sep 2024 | +13.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
31.49x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing PGNY
| FY Dec 2025 | 39.51x |
| FY Dec 2024 | 30.26x |
| FY Dec 2023 | 59.97x |
| FY Dec 2022 | 103.83x |
| FY Dec 2021 | 76.29x |
| Jun 2026 | 31.34x |
| Mar 2026 | 22.05x |
| Dec 2025 | 39.51x |
| Sep 2025 | 34.16x |
| Jun 2025 | 37.29x |
| Mar 2025 | 39.19x |
| Dec 2024 | 30.26x |
| Sep 2024 | 28.90x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.1B
market value at close 2026-10-23 on 2026-07-31 shares, plus current debt only, 2018-12-31 (91 months older than the period end), minus cash 2026-06-30
Enterprise value PGNY
| FY Dec 2025 | $2.1B |
| FY Dec 2024 | $1.3B |
| FY Dec 2023 | $3.5B |
| FY Dec 2022 | $2.8B |
| FY Dec 2021 | $4.5B |
| Jun 2026 | $2.1B |
| Mar 2026 | $1.3B |
| Dec 2025 | $2.1B |
| Sep 2025 | $1.7B |
| Jun 2025 | $1.8B |
| Mar 2025 | $1.8B |
| Dec 2024 | $1.3B |
| Sep 2024 | $1.4B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+8.0%
TTM free cash flow over market value at close 2026-10-23
FCF yield PGNY
| FY Dec 2025 | +8.7% |
| FY Dec 2024 | +11.8% |
| FY Dec 2023 | +5.2% |
| FY Dec 2022 | +2.7% |
| FY Dec 2021 | +0.5% |
| Jun 2026 | +7.9% |
| Mar 2026 | +13.3% |
| Dec 2025 | +8.7% |
| Sep 2025 | +10.5% |
| Jun 2025 | +10.1% |
| Mar 2025 | +10.3% |
| Dec 2024 | +11.8% |
| Sep 2024 | +10.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.56x
P/E over trailing EPS growth of 56%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing PGNY
| FY Dec 2025 | 2.81x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.56x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 1.89x |
| Jun 2026 | 0.56x |
| Mar 2026 | 0.63x |
| Dec 2025 | 2.81x |
| Sep 2025 | 3.96x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 2.50x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.3B | $1.2B | $1.1B | $786.9M |
| Gross profit | $304.5M | $253.4M | $238.8M | $167.3M |
| Operating income | $85.3M | $67.5M | $62.2M | $23.3M |
| Net income | $58.5M | $54.3M | $62.0M | $30.4M |
| EPS (diluted) | 0.65 | 0.57 | 0.62 | 0.30 |
| Operating cash flow | $210.2M | $179.1M | $188.8M | $80.4M |
| Cash | $112.2M | $162.3M | $97.3M | $120.1M |
| Buybacks | $81.7M | $300.3M | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-27
PGNY Stock Sonar score 6/7 axes
Find similar shapesComparePGNY ranks highest on financial health (95th percentile) and profitability (84th), and lowest on insider conviction (24th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PGNY filings, in plain words
Are Progyny insiders buying or selling PGNY?
In the 180 days to 2026-10-27, Progyny insiders were net sellers, a net $1.5M across purchases and sales reported on Form 4, by 6 sellers.
Have members of Congress traded PGNY?
Yes, but not in the year to 2026-10-27; the latest on record is a sale by Josh Gottheimer dated 2024-12-06.
Are there planned insider sales of PGNY?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $466.3K of stock; the latest, by Cummings Melissa B, was filed 2026-10-14.
Read the full summary
In the 180 days to 2026-10-27, Progyny insiders were net sellers of PGNY, a net $1.5M across purchases and sales reported on Form 4 by 6 sellers. 13% of the 15 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Members of Congress have disclosed trades in PGNY, none in the last year; the latest on record is a sale by Josh Gottheimer dated 2024-12-06. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $466.3K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
